申报-话题@MedSci

#申报#

103篇内容 | 1374人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1688588, encodeId=7d7a168858804, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=陆麒教授：科研课题申报和伦理审查指南全概括, objectType=article, longId=300442, objectId=8a1e30044297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1e30044297, replyNumber=0, likeNumber=28, createdTime=2022-03-26, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1e30044297, moduleTitle=陆麒教授：科研课题申报和伦理审查指南全概括, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1e30044297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688590, encodeId=3c05168859017, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=Tirzepatide（替西帕肽）中国申报上市，是当下降糖之王！, objectType=article, longId=738469, objectId=db0ee38469ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db0ee38469ee, replyNumber=0, likeNumber=54, createdTime=2023-04-07, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db0ee38469ee, moduleTitle=Tirzepatide（替西帕肽）中国申报上市，是当下降糖之王！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db0ee38469ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688589, encodeId=92ae1688589df, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=关于高级职称申报评审，一地列出明确要求, objectType=article, longId=736621, objectId=e7bfe366210b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7bfe366210b, replyNumber=0, likeNumber=34, createdTime=2023-06-14, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7bfe366210b, moduleTitle=关于高级职称申报评审，一地列出明确要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7bfe366210b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688587, encodeId=084e168858e82, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=“干细胞研究与器官修复” 重点专项2022 年度项目申报指南（征求意见稿）, objectType=article, longId=295441, objectId=c2a729544118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2a729544118, replyNumber=0, likeNumber=30, createdTime=2022-07-17, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2a729544118, moduleTitle=“干细胞研究与器官修复” 重点专项2022 年度项目申报指南（征求意见稿）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2a729544118)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688583, encodeId=032b16885833b, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟, objectType=article, longId=210360, objectId=43fb210360da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43fb210360da, replyNumber=0, likeNumber=44, createdTime=2022-03-20, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43fb210360da, moduleTitle=罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43fb210360da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688586, encodeId=9fe816885860d, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=卫健委发文：这些医务人员可提前1年申报高级职称，对论文不做硬性要求, objectType=article, longId=213806, objectId=3f372138060e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f372138060e, replyNumber=0, likeNumber=40, createdTime=2021-12-26, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f372138060e, moduleTitle=卫健委发文：这些医务人员可提前1年申报高级职称，对论文不做硬性要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f372138060e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688581, encodeId=2e02168858124, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=住友制药新靶点精神分裂症新药申报临床, objectType=article, longId=209097, objectId=c10b20909e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c10b20909e5e, replyNumber=0, likeNumber=39, createdTime=2021-11-04, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c10b20909e5e, moduleTitle=住友制药新靶点精神分裂症新药申报临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c10b20909e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688585, encodeId=4bd9168858501, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, objectType=article, longId=213744, objectId=3257213e448e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3257213e448e, replyNumber=0, likeNumber=41, createdTime=2021-09-17, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3257213e448e, moduleTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3257213e448e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688584, encodeId=b9e216885843a, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=国科大重庆医院与重庆学院联合申报获批“肝胆胰疾病智慧诊疗工程重庆市重点实验室”, objectType=article, longId=212475, objectId=0e592124e5df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e592124e5df, replyNumber=0, likeNumber=36, createdTime=2022-01-10, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e592124e5df, moduleTitle=国科大重庆医院与重庆学院联合申报获批“肝胆胰疾病智慧诊疗工程重庆市重点实验室”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e592124e5df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688574, encodeId=057016885e46b, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格, objectType=article, longId=200548, objectId=626120054831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=626120054831, replyNumber=0, likeNumber=37, createdTime=2021-02-08, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=626120054831, moduleTitle=国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=626120054831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688575, encodeId=503d16885e553, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=皮下注射PD-L1在中国申报上市，拟优先审评, objectType=article, longId=200936, objectId=f3b920093688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b920093688, replyNumber=0, likeNumber=35, createdTime=2021-04-25, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b920093688, moduleTitle=皮下注射PD-L1在中国申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b920093688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688573, encodeId=d17916885e3ac, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, objectType=article, longId=200286, objectId=f1bd20028653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bd20028653, replyNumber=0, likeNumber=32, createdTime=2021-06-26, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bd20028653, moduleTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bd20028653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688577, encodeId=b00116885e7a2, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=每周注射1次！诺和诺德长效胰岛素在中国申报临床, objectType=article, longId=201026, objectId=9724201026e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9724201026e4, replyNumber=0, likeNumber=41, createdTime=2021-08-11, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9724201026e4, moduleTitle=每周注射1次！诺和诺德长效胰岛素在中国申报临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9724201026e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688582, encodeId=c42e16885820d, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理, objectType=article, longId=209860, objectId=c7782098601b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7782098601b, replyNumber=0, likeNumber=28, createdTime=2021-04-24, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7782098601b, moduleTitle=中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7782098601b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688579, encodeId=13d816885e9f1, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, objectType=article, longId=201089, objectId=b23f201089dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b23f201089dc, replyNumber=0, likeNumber=38, createdTime=2021-05-10, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b23f201089dc, moduleTitle=贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b23f201089dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688580, encodeId=203c1688580af, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=CDE新增14条常见一般性技术问题解答：化学药品仿制药能否直接申报上市许可申请？, objectType=article, longId=204181, objectId=dc0720418157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc0720418157, replyNumber=0, likeNumber=45, createdTime=2021-06-18, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc0720418157, moduleTitle=CDE新增14条常见一般性技术问题解答：化学药品仿制药能否直接申报上市许可申请？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc0720418157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688572, encodeId=06d316885e2df, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=1230多人申报，每人资助300万！2020年度“科学探索奖”评审工作即将启动, objectType=article, longId=194327, objectId=465019432e2e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=465019432e2e, replyNumber=0, likeNumber=38, createdTime=2020-10-01, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=465019432e2e, moduleTitle=1230多人申报，每人资助300万！2020年度“科学探索奖”评审工作即将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=465019432e2e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688576, encodeId=a94516885e626, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, objectType=article, longId=200943, objectId=904a20094367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904a20094367, replyNumber=0, likeNumber=37, createdTime=2021-08-08, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904a20094367, moduleTitle=豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904a20094367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688578, encodeId=b13716885e8bb, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=每周注射1次！诺和诺德长效胰岛素icodec在中国申报临床, objectType=article, longId=201065, objectId=3f9420106580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f9420106580, replyNumber=0, likeNumber=37, createdTime=2020-12-04, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f9420106580, moduleTitle=每周注射1次！诺和诺德长效胰岛素icodec在中国申报临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f9420106580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1688567, encodeId=a999168856e23, content=<a href='/topic/show?id=327b699645c' target=_blank style='color:#2F92EE;'>#申报#</a>, objectTitle=DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报, objectType=article, longId=180548, objectId=ad60180548d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad60180548d0, replyNumber=0, likeNumber=49, createdTime=2019-12-10, rootId=0, userName=1508842480_96220446, userId=1a1628602102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad60180548d0, moduleTitle=DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad60180548d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

申报

2020-05-29

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

陆麒教授：科研课题申报和伦理审查指南全概括

2022-03-26

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

Tirzepatide（替西帕肽）中国申报上市，是当下降糖之王！

2023-04-07

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

关于高级职称申报评审，一地列出明确要求

2023-06-14

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

“干细胞研究与器官修复” 重点专项2022 年度项目申报指南（征求意见稿）

2022-07-17

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟

2022-03-20

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

卫健委发文：这些医务人员可提前1年申报高级职称，对论文不做硬性要求

2021-12-26

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

住友制药新靶点精神分裂症新药申报临床

2021-11-04

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗

2021-09-17

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

国科大重庆医院与重庆学院联合申报获批“肝胆胰疾病智慧诊疗工程重庆市重点实验室”

2022-01-10

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

国内申报上市的第二个CAR-T疗法获“优先审评+突破性药物”双重审评资格

2021-02-08

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

皮下注射PD-L1在中国申报上市，拟优先审评

2021-04-25

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化

2021-06-26

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

每周注射1次！诺和诺德长效胰岛素在中国申报临床

2021-08-11

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

中国完全基于乐城真实世界研究数据申报NDA的新药OT-401（Yutiq）获NMPA受理

2021-04-24

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

贝达药业埃克替尼第3项适应症申报上市，用于NSCLC患者术后辅助治疗

2021-05-10

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

CDE新增14条常见一般性技术问题解答：化学药品仿制药能否直接申报上市许可申请？

2021-06-18

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

1230多人申报，每人资助300万！2020年度“科学探索奖”评审工作即将启动

2020-10-01

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

豪森药业1类乙肝新药「艾美酚胺替诺福韦片」申报上市，拟优先审评

2021-08-08

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

每周注射1次！诺和诺德长效胰岛素icodec在中国申报临床

2020-12-04

1508842480_96220446 (审核中...)

前往app查看评论内容

#申报#

DBV Technologies宣布FDA接受Viaskin治疗花生过敏的BLA申报

2019-12-10

科室
- - 订阅+
  - 更多科室
工具
服务